Cohort study: Stroke rates after introduction of bevacizumab and ranibizumab for AMD

Source: Ophthalmology
Area: News
A recent cohort study of Medicare patients concluded that vascular endothelial growth factor (VEGF)-inhibiting drugs for age-related macular degeneration (AMD) were not associated with an increased risk of stroke. However, the population-level safety of the individual VEGF inhibitors remains an important public health issue.   To investigate further, researchers conducted a population-based time series analysis evaluating whether stroke rates among patients with retinal disease were influenced by the rapid and sequential uptakes of bevacizumab and ranibizumab for AMD,   Canadian health care linked databases were used (Read more...)

Full Story →